Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Vascular adhesion protein-1 (VAP-1) is a novel driver of tissue inflammation and fibrosis.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Shah T, Sagar V, Neil D, Liu B, Barriuso J,
Keywords: carcinoid, GEP-NET, VAP-1, ECM, tumour stroma, biomarker,
Introduction: Lanreotide autogel (LAN) 120 mg every (q)28 days (standard regimen) improves progression-free survival vs placebo in patients with advanced, somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumours (NETs).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Ruszniewski P, Ćwikła J, Lombard-Bohas C, Borbath I, Shah T,
Keywords: Neuroendocrine tumours, lanreotide,
Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Spada F
Authors: Spada F, Laskaratos F, Crona J, Oleinikov K, Zandee W,
Keywords: Carcinoid Heart Disease, NETs, Carcinoid Syndrome, Midgut NETs,
Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Shah T, Caplin M, Khan M, Houchard A, Furnace M,
Keywords: neuroendocrine tumours, lanreotide, biomarkers,
Introduction: CLARINET demonstrated the antitumour effect of LAN 120mg/28 days (standard interval) in metastatic gastroenteropancreatic NETs. If disease progresses (PD) on this dose, aggressive treatments (eg targeted therapies) are usually offered.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author:
Authors: Pavel M, Dromain C, Majdi A, Houchard A,
Keywords: Lanreotide, dosing interval,